173 to 1: Bristol-Myers chief Caforio picked up a $19.4M compensation deal after leading the charge for $74B Celgene buyout
Bristol-Myers Squibb went right down to the wire on its proxy statement. And just days after investors provided a stamp of approval for its huge …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
